retatrutide energy Is Weight Loss the Future of Peptide Weight Loss Therapy? Does retatrutide make you tired?

People with type 2 diabetes and a history of diabetic eye disease may need monitoring

DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse

Track ongoing studies and FDA progress What Is Retatrutide

How does Mounjaro work

Urva S, Coskun T, Loh MT, et al

Detailed statistics are in Supplementary Table 1